Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19
Open Access
- 1 July 2025
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 118, 105819
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 30 references indexed in Scilit:
- Emerging SARS-CoV-2 Resistance After Antiviral TreatmentJAMA Network Open, 2024
- SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugsCell Chemical Biology, 2024
- SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysisThe Lancet Microbe, 2024
- No emergence of resistance mutations in COVID‐19 patients receiving nirmatrelvir/ritonavirJournal of Medical Virology, 2023
- Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2Med, 2023
- Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 GenomesThe Journal of Molecular Diagnostics, 2022
- Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variantsJournal of Biological Chemistry, 2022
- De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case reportNature Communications, 2022
- Update and latest advances in antiretroviral therapyTrends in Pharmacological Sciences, 2022
- Comparison of antiviral resistance across acute and chronic viral infectionsAntiviral Research, 2018